



## Cardiac Ion Channel Genetic Testing

Last Review Date: March 10, 2017

Number: MG.MM.LA.06dC

### Medical Guideline Disclaimer

Property of EmblemHealth. All rights reserved. The treating physician or primary care provider must submit to EmblemHealth the clinical evidence that the patient meets the criteria for the treatment or surgical procedure. Without this documentation and information, EmblemHealth will not be able to properly review the request for prior authorization. The clinical review criteria expressed below reflects how EmblemHealth determines whether certain services or supplies are medically necessary. EmblemHealth established the clinical review criteria based upon a review of currently available clinical information (including clinical outcome studies in the peer-reviewed published medical literature, regulatory status of the technology, evidence-based guidelines of public health and health research agencies, evidence-based guidelines and positions of leading national health professional organizations, views of physicians practicing in relevant clinical areas, and other relevant factors). EmblemHealth expressly reserves the right to revise these conclusions as clinical information changes, and welcomes further relevant information. Each benefit program defines which services are covered. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that this service or supply is covered and/or paid for by EmblemHealth, as some programs exclude coverage for services or supplies that EmblemHealth considers medically necessary. If there is a discrepancy between this guideline and a member's benefits program, the benefits program will govern. In addition, coverage may be mandated by applicable legal requirements of a state, the Federal Government or the Centers for Medicare & Medicaid Services (CMS) for Medicare and Medicaid members. All coding and web site links are accurate at time of publication. EmblemHealth Services Company LLC, ("EmblemHealth") has adopted the herein policy in providing management, administrative and other services to HIP Health Plan of New York, HIP Insurance Company of New York, Group Health Incorporated and GHI HMO Select, related to health benefit plans offered by these entities. All of the aforementioned entities are affiliated companies under common control of EmblemHealth Inc.

### Definitions

Long QT syndrome (LQTS)	A congenital disorder characterized by prolongation of the QT interval on electrocardiogram (ECG) and a propensity to ventricular tachyarrhythmias, which may lead to syncope, cardiac arrest or sudden cardiac death, typically in young individuals. Variants of LQTS include the Romano-Ward syndrome (autosomal dominant inheritance, QT prolongation and ventricular tachyarrhythmias) and the Jervell and Lang-Nielsen (JLN) syndrome (autosomal recessive
Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)	A lethal form of inherited cardiac channelopathy characterized by irregular heart rhythms (brought on by physical exertion or intense emotion) which may cause syncope, cardiac arrest or sudden cardiac death. Autosomal dominant and recessive CPVT variants arise from mutations in the cardiac ryanodine receptor (RyR2) gene and the cardiac calsequestrin (CASQ2) gene respectively.
Brugada syndrome	An inherited cardiac condition characterized by abnormal EKG findings, an increased risk of ventricular fibrillation and sudden death.
Short QT syndrome (SQTS)	An autosomal dominant channelopathy characterized by a shortened QT interval and action potential on EKG findings and an increased risk for adverse cardiac events including arrhythmias and SCD.

### Guideline

#### 1. Long QT Syndrome (LQTS)

Considered medically necessary for **any** of the following indications:

- Signs or symptoms indicating a moderate-to-high pretest probability of LQTS (e.g., Schwartz score of 2–3)<sup>1</sup>
- A close relative (e.g., 1<sup>st</sup>, 2<sup>nd</sup> or 3<sup>d</sup>-degree) with a known LQTS mutation

<sup>1</sup> A commonly used criterion to diagnose LQTS is the LQTS "diagnostic score", which is calculated by assigning different points to various criteria (e.g., ≥ 4 points indicates high probability, ≤ 1 denotes low and 2 or 3 suggests intermediate probability of LQTS).

- c. A close relative diagnosed with LQTS by clinical means whose genetic status is unavailable but has sustained an unexplained syncopal episode, ventricular fibrillation with successful resuscitation or sudden death

## 2. Catecholaminergic polymorphic ventricular tachycardia (CPVT)

Considered medically necessary for **any** of the following indications:

- a. Children or young adults (< 40 years of age) who have a 1<sup>st</sup> degree relative with a clinical diagnosis of CPVT
- b. Children or young adults (< 40 years of age) who have a 1<sup>st</sup>, 2<sup>nd</sup> or 3<sup>d</sup>-degree relative with a known CPVT mutation
- c. Signs or symptoms indicating a moderate-to-high pretest probability of CPVT

## Limitations/Exclusions

Genetic testing for Brugada Syndrome and SQT syndrome is considered investigational and not medically necessary.

## Revision History

3/11/2016: Title changed from Genetic Testing for Long QT syndrome (LQTS) to Cardiac Ion Channel Genetic Testing and added indication for CPVT genetic testing.

## Applicable Procedure Codes

81280	Long QT syndrome gene analyses (eg, KCNQ1, KCNH2, SCN5A, KCNE1, KCNE2, KCNJ2, CACNA1C, CAV3, SCN4B, AKAP, SNTA1, and ANK2); full sequence analysis (Code Deleted 01/01/2017)
81281	Long QT syndrome gene analyses (eg, KCNQ1, KCNH2, SCN5A, KCNE1, KCNE2, KCNJ2, CACNA1C, CAV3, SCN4B, AKAP, SNTA1, and ANK2); known familial sequence variant (Code Deleted 01/01/2017)
81282	Long QT syndrome gene analyses (eg, KCNQ1, KCNH2, SCN5A, KCNE1, KCNE2, KCNJ2, CACNA1C, CAV3, SCN4B, AKAP, SNTA1, and ANK2); duplication/deletion variants (Code Deleted 01/01/2017)
81403	Molecular pathology procedure, Level 4 (eg, analysis of single exon by DNA sequence analysis, analysis of >10 amplicons using multiplex PCR in 2 or more independent reactions, mutation scanning or duplication/deletion variants of 2-5 exons)
81405	Molecular pathology procedure, Level 6 (eg, analysis of 6-10 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of 11-25 exons, regionally targeted cytogenomic array analysis)
81408	Molecular pathology procedure, Level 9 (eg, analysis of >50 exons in a single gene by DNA sequence analysis)

## Applicable ICD-10 Diagnosis Codes

I45.81	Long QT syndrome
I47.0	Re-entry ventricular arrhythmia
I47.2	Ventricular tachycardia
I47.9	Paroxysmal tachycardia, unspecified

## References

1. Brugada P, Brugada R, Antzelevitch C, et al. The Brugada syndrome. Arch Mal Coeur Vaiss. 2005; 98(2):115-122.
2. Brugada R, Brugada P, Brugada J, Hong K. Brugada syndrome. In: GeneReviews at GeneTests: Medical Genetics Information Resource [database online]. Seattle, WA: University of Washington; December 7, 2007. Available at: <http://www.geneclinics.org>.
3. Chiang CE. Congenital and acquired LQTS; current concepts and management. Cardiology Review. 2004 Jul-Aug;12(4):222-

34.

4. Gollob MH, Redpath CJ, Roberts JD. The short QT syndrome: proposed diagnostic criteria. *J Am Coll Cardiol.* 2011; 57(7):802-812
5. Maron BJ, Moller JH, Seidman CE, et al. Impact of laboratory molecular diagnosis on contemporary diagnostic criteria for genetically transmitted cardiovascular diseases: hypertrophic cardiomyopathy, long-QT syndrome, and marfan syndrome: a statement for healthcare professionals from the councils on clinical cardiology, cardiovascular disease in the young, and basic science, American Heart Association *Circulation.* 1998;98:1460-1471.  
<http://circ.ahajournals.org/cgi/search?journalcode=circulationaha&fulltext=Impact+of+laboratory+molecular+diagnosis+on+contemporary+diagnostic+>.
6. Schwartz PJ, Moss AJ, Vincent GM, Crampton RS. Diagnostic criteria for the long QT syndrome. An update. *Circulation.* 1993 Aug;88(2):782
7. Specialty matched clinical peer review.